The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid by other developed nations. The companies are Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi. Similar to previous announcements, the nine companies will provide all state Medicaid programs access to MFN prices on their products and must offer medicines at deep discounts off the list price when selling directly to American consumers. In addition, GSK, Bristol Myers Squibb and Merck will donate ingredients for medications to the Strategic Active Pharmaceutical Ingredients Reserve.

Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…